Literature DB >> 8497705

Respiratory arrests in young asthmatics on salmeterol.

C E Clark1, A D Ferguson, J A Siddorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8497705     DOI： 10.1016/0954-6111(93)90098-k

Source DB:  PubMed          Journal:  Respir Med        ISSN： 0954-6111            Impact factor:   3.415


× No keyword cloud information.
  9 in total

Review 1.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 2.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 3.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

4.  Long-acting beta 2-agonists and their role in asthma management.

Authors:  S P Galant
Journal:  West J Med       Date:  1995-10

5.  Bronchodilator treatment in asthma. Increase in deaths during salmeterol treatment unexplained.

Authors:  M R Sears; D R Taylor
Journal:  BMJ       Date:  1993-06-12

Review 6.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

7.  Asthma exacerbations during first therapy with long acting beta 2-agonists.

Authors:  C M Gerrits; R M Herings; H G Leufkens; J W Lammers
Journal:  Pharm World Sci       Date:  1999-06

Review 8.  Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

Authors:  B J Lipworth
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228

Review 9.  A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.

Authors:  Milind P Sovani; Christopher I Whale; Anne E Tattersfield
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.